You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
Can multisource immediate release amodiaquine products qualify for BCS based biowaivers?
- In: Biopharmaceutics Classification System Posters
- At: Hyderabad (India) (2011)
- Type: Poster
- Poster code: BCS-P-01
- By: NAIR, Anita (Goethe University, Frankfurt Am Main, Germany)
- Co-author(s): Dressman B, Jennifer (Goethe University, Frankfurt Am Main, Germany)
- Abstract:
Background information; Amodiaquine, frequently prescribed along with artesunate, is recommended for the treatment of uncomplicated falciparum malaria by the WHO. It is widely adopted for malarial treatment across sub-Saharan regions due to its high efficacy and tolerance. The biowaiver procedure based Biopharmaceutical Classification System (BCS)
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026